EX-99.1
Published on April 23, 2015
Exhibit 99.1
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015
Revenue increased 6% to $422 million; up 13% on a constant currency basis
GAAP diluted earnings per share of $0.64, or non-GAAP earnings per share of $0.65
Operating cash flow of $90.9 million
Company repurchased 300,000 shares in the third quarter
San Diego, April 23, 2015 ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2015. Revenue for the quarter was $422.5 million, a 6 percent increase compared to the quarter ended March 31, 2014 (a 13 percent increase on a constant currency basis). Net income was $91.0 million, an increase of 1 percent compared to the quarter ended March 31, 2014. Diluted earnings per share for the quarter were $0.64, an increase of 2 percent compared to the quarter ended March 31, 2014. Non-GAAP diluted earnings per share for the quarter were $0.65, a 2 percent increase compared to the quarter ended March 31, 2014.
We are pleased to report excellent progress with our new product launches, as we continued to see double-digit revenue growth, said Mick Farrell, ResMeds chief executive officer. Strong demand for our new flow generator launches in the U.S. and continued growth in our Asia Pacific and Europe regions drove our results in the quarter.
We saw strong customer adoption of our range of new flow generators: the Astral, AirSense 10 and the recently launched AirCurve 10 series of cloud-connected bilevel devices. This quarter, we continued to build our informatics capabilities with the acquisition of Jaysec, a provider of cloud-based software solutions for the home medical equipment industry, as well as the integration of our AirView patient management system with leading informatics partners. Farrell concluded, We are executing on our long-term strategy: growing our core sleep disordered breathing market and investing in future opportunities in chronic obstructive pulmonary disease as well as cardio-respiratory conditions. Our innovative products and solutions improve patient outcomes, lower healthcare costs, and reduce the impact of chronic disease.
Analysis of third quarter results
In the third quarter of fiscal year 2015, revenue in the Americas was $250.9 million, a 16 percent increase over the prior years quarter. Revenue in combined Europe and Asia Pacific was $171.6 million, a 6 percent decrease compared to the quarter ended March 31, 2014 (a 9 percent increase on a constant currency basis).
Gross margin in the third quarter was 59.5 percent, lower than the prior year, mainly due to declines in average selling prices, an unfavorable product and geographic mix, and an unfavorable impact from foreign exchange rate movements.
Selling, general and administrative expenses were $116.3 million for the quarter, a 1 percent increase (a 10 percent increase on a constant currency basis) over the quarter ended March 31, 2014. SG&A expenses improved to 27.5 percent of revenue in the quarter, compared to 28.9 percent in the quarter ended March 31, 2014.
Research and development expenses were $27.0 million for the quarter, or 6.4 percent of revenue. R&D expenses decreased by 8 percent (a 4 percent increase on a constant currency basis) compared to the quarter ended March 31, 2014.
Operating profit for the quarter was $105.9 million and cash flow from operations was $90.9 million.
Amortization of acquired intangible assets was $2.2 million ($1.6 million, net of tax) during the quarter. Stock-based compensation costs incurred during the quarter of $11.7 million ($8.2 million, net of tax) consisted of expenses associated with employee equity grants, and the companys employee stock purchase plan.
Share repurchase program
During the quarter, the company repurchased 300,000 shares at a cost of $20.3 million, as part of its ongoing capital management program.
Dividend program
The ResMed board of directors today declared a quarterly dividend of $0.28 per share. The dividend will have a record date of May 21, 2015, payable on June 18, 2015. The dividend will be paid in U.S. currency to holders of ResMeds common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 19, 2015 for common stock holders and for CDI holders. ResMed has received a waiver from the ASXs settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 19, 2015 through May 21, 2015, inclusive.
Webcast details
ResMed will discuss its financial and business results and its business outlook on its webcast at 1:30 p.m. U.S. Pacific Standard Time today. The live webcast of the call can be accessed on ResMeds website at www.resmed.com. Please allow extra time before the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast. The online archive of the broadcast will be available after the live call on ResMeds website. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 630-652-3042 (U.S.) and +1 630-652-3042 (international) and entering a passcode of 39335543. The telephone replay will be available until May 7, 2015.
About ResMed
The global team at ResMed (NYSE:RMD) is united in their commitment to changing lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMeds world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.
Safe harbor statement
Statements contained in this release that are not historical facts are forward-looking statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMeds projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products -- are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMeds periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
Investors:
Agnes Lee
Senior Director, Investor Relations
(858) 836-5971
investorrelations@resmed.com
News Media:
Alison Graves
Director, Global Corporate Communications
(858) 836-6789
news@resmed.com
- More -
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Statements of Income (Unaudited)
(In thousands, except per share data)
| Three Months Ended March 31, |
Nine Months Ended March 31, |
|||||||||||||||
| 2015
|
2014
|
2015
|
2014
|
|||||||||||||
| Net revenue |
$422,497 | $397,758 | $1,225,848 | $1,139,762 | ||||||||||||
| Cost of sales
|
|
171,066
|
|
|
145,970
|
|
|
473,882
|
|
|
411,234
|
|
||||
| Gross profit
|
|
251,431
|
|
|
251,788
|
|
|
751,966
|
|
|
728,528
|
|
||||
| Operating expenses: |
||||||||||||||||
| Selling, general and administrative |
116,336 | 115,101 | 349,377 | 328,172 | ||||||||||||
| Research and development |
27,024 | 29,530 | 86,342 | 86,430 | ||||||||||||
| Amortization of acquired intangible assets
|
|
2,203
|
|
|
2,459
|
|
|
6,558
|
|
|
7,325
|
|
||||
| Total operating expenses
|
|
145,563
|
|
|
147,090
|
|
|
442,277
|
|
|
421,927
|
|
||||
| Income from operations
|
|
105,868
|
|
|
104,698
|
|
|
309,689
|
|
|
306,601
|
|
||||
| Other income (expenses), net: |
||||||||||||||||
| Interest income (expense), net |
4,761 | 6,015 | 15,765 | 19,182 | ||||||||||||
| Other, net
|
|
3,729
|
|
|
2,199
|
|
|
6,346
|
|
|
(1,340)
|
|
||||
| Total other income (expenses), net
|
|
8,490
|
|
|
8,214
|
|
|
22,111
|
|
|
17,842
|
|
||||
| Income before income taxes |
114,358 | 112,912 | 331,800 | 324,443 | ||||||||||||
| Income taxes
|
|
23,375
|
|
|
22,943
|
|
|
66,376
|
|
|
66,908
|
|
||||
| Net income
|
|
$90,983
|
|
|
$89,969
|
|
|
$265,424
|
|
|
$257,535
|
|
||||
| Basic earnings per share |
$0.65 | $0.64 | $1.89 | $1.82 | ||||||||||||
| Diluted earnings per share |
$0.64 | $0.63 | $1.86 | $1.78 | ||||||||||||
| Basic shares outstanding |
140,792 | 140,959 | 140,341 | 141,774 | ||||||||||||
| Diluted shares outstanding
|
|
142,813
|
|
|
143,375
|
|
|
142,614
|
|
|
144,758
|
|
||||
- More -
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited - In thousands)
| March 31, | June 30, | |||||||
| 2015
|
2014
|
|||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$866,325 | $905,730 | ||||||
| Accounts receivable, net |
345,485 | 359,593 | ||||||
| Inventories |
225,191 | 165,418 | ||||||
| Prepayments, deferred income taxes and other current assets
|
|
115,769
|
|
|
125,468
|
|
||
| Total current assets
|
|
1,552,770
|
|
|
1,556,209
|
|
||
| Property, plant and equipment, net |
384,160 | 434,277 | ||||||
| Goodwill and other intangible assets, net |
302,339 | 334,510 | ||||||
| Deferred income taxes and other non-current assets
|
|
38,760
|
|
|
35,966
|
|
||
| Total non-current assets
|
|
725,259
|
|
|
804,753
|
|
||
| Total assets
|
|
$2,278,029
|
|
|
$2,360,962
|
|
||
| LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$70,900 | $85,405 | ||||||
| Accrued expenses |
131,770 | 130,656 | ||||||
| Deferred revenue |
37,295 | 42,370 | ||||||
| Income taxes payable |
15,800 | 10,392 | ||||||
| Deferred income taxes |
639 | 717 | ||||||
| Current portion of long-term debt
|
|
0
|
|
|
18
|
|
||
| Total current liabilities
|
|
256,404
|
|
|
269,558
|
|
||
| Non-current liabilities: |
||||||||
| Deferred income taxes |
8,831 | 10,716 | ||||||
| Deferred revenue |
14,184 | 16,352 | ||||||
| Income taxes payable |
1,754 | 5,318 | ||||||
| Non-current portion of long-term debt
|
|
460,581
|
|
|
300,770
|
|
||
| Total non-current liabilities
|
|
485,350
|
|
|
333,156
|
|
||
| Total liabilities
|
|
741,754
|
|
|
602,714
|
|
||
| Stockholders Equity: |
||||||||
| Common stock |
563 | 561 | ||||||
| Additional paid-in capital |
1,195,880 | 1,117,644 | ||||||
| Retained earnings |
1,927,958 | 1,780,396 | ||||||
| Treasury stock |
(1,388,623) | (1,291,910) | ||||||
| Accumulated other comprehensive income
|
|
(199,503)
|
|
|
151,557
|
|
||
| Total stockholders equity
|
|
$1,536,275
|
|
|
$1,758,248
|
|
||
| Total liabilities and stockholders equity
|
|
$2,278,029
|
|
|
$2,360,962
|
|
||
- More
RESMED INC AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)
| Nine Months March 31, |
Nine Months March 31, |
|||||||
| 2015
|
2014
|
|||||||
| Cash flows from operating activities: |
||||||||
| Net income |
$265,424 | $257,535 | ||||||
| Adjustment to reconcile net income to net cash provided by operating activities: |
||||||||
| Depreciation and amortization |
55,310 | 53,631 | ||||||
| Gain on disposal of business |
(709) | - | ||||||
| Stock-based compensation costs |
34,802 | 32,679 | ||||||
| Foreign currency revaluation |
(1,252) | (3,305) | ||||||
| Excess tax benefit from stock-based compensation arrangements |
(20,738) | (11,388) | ||||||
| Changes in operating assets and liabilities, net of effect of acquisitions: |
||||||||
| Accounts receivable, net |
(14,814) | (12,873) | ||||||
| Inventories, net |
(80,793) | (15,735) | ||||||
| Prepaid expenses, net deferred income taxes and other current assets |
(3,487) | (4,020) | ||||||
| Accounts payable, accrued expenses and other liabilities
|
|
49,736
|
|
|
(20,839)
|
|
||
| Net cash provided by operating activities |
|
283,479
|
|
|
275,685
|
|
||
| Cash flows from investing activities: |
||||||||
| Purchases of property, plant and equipment |
(50,266) | (54,210) | ||||||
| Patent registration costs |
(7,109) | (5,691) | ||||||
| Business acquisitions, net of cash acquired |
(26,956) | (3,172) | ||||||
| Investments in cost-method investments |
(10,500) | (5,275) | ||||||
| Proceeds from sale of business |
468 | - | ||||||
| Purchases of foreign currency options |
- | (1,337) | ||||||
| Payments on maturity of foreign currency contracts |
|
(25,232)
|
|
|
(2,466)
|
|
||
| Net cash used in investing activities
|
|
(119,595)
|
|
|
(72,151)
|
|
||
| Cash flows from financing activities: |
||||||||
| Proceeds from issuance of common stock, net |
23,176 | 15,624 | ||||||
| Excess tax benefit from stock-based compensation arrangements |
20,738 | 11,388 | ||||||
| Purchases of treasury stock |
(103,295) | (169,398) | ||||||
| Payment of business combination contingent consideration |
(458) | (1,117) | ||||||
| Proceeds from borrowings, net of borrowing costs |
160,000 | 507,838 | ||||||
| Repayment of borrowings |
(1,527) | (415,029) | ||||||
| Dividends paid |
|
(117,862)
|
|
|
(106,387)
|
|
||
| Net cash (used in) / provided by financing activities |
|
(19,228)
|
|
|
(157,081)
|
|
||
| Effect of exchange rate changes on cash |
|
(184,061)
|
|
|
16,062
|
|
||
| Net increase / (decrease) in cash and cash equivalents |
(39,405) | 62,515 | ||||||
| Cash and cash equivalents at beginning of period |
|
905,730
|
|
|
876,048
|
|
||
| Cash and cash equivalents at end of period |
|
866,325
|
|
|
938,563
|
|
||
- More
Reconciliation of Non-GAAP Financial Measures (Unaudited)
(In US$ thousands, except share and per share data)
The measure, non-GAAP operating income is reconciled with GAAP income from operations below:
| Three Months Ended Mar 31, |
Nine Months Ended Mar 31, |
|||||||||||||||
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
|||||
| GAAP income from operations |
105,868 | 104,698 | 309,689 | 306,601 | ||||||||||||
| Amortization of acquired intangible assets (A)
|
|
2,203
|
|
|
2,459
|
|
|
6,558
|
|
|
7,325
|
|
||||
| Non-GAAP operating income (excluding the impact of amortization of acquired intangible assets) |
|
108,071
|
|
|
107,157
|
|
|
316,247
|
|
|
313,926
|
|
||||
The measure, non-GAAP net income and non-GAAP diluted earnings per share are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
| Three Months Ended Mar 31, |
Nine Months Ended Mar 31, |
|||||||||||||||
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
|||||
| GAAP net income |
90,983 | 89,969 | 265,424 | 257,535 | ||||||||||||
| Amortization of acquired intangible assets, net of tax (A)
|
|
1,643
|
|
|
1,868
|
|
|
4,951
|
|
|
5,563
|
|
||||
| Non-GAAP net income (excluding the impact of amortization of acquired intangible assets)
|
|
92,626
|
|
|
91,837
|
|
|
270,375
|
|
|
263,098
|
|
||||
| Diluted shares outstanding
|
|
142,813
|
|
|
143,375
|
|
|
142,614
|
|
|
144,758
|
|
||||
| GAAP diluted earnings per share
|
|
$0.64
|
|
|
$0.63
|
|
|
$1.86
|
|
|
$1.78
|
|
||||
| Non-GAAP diluted earnings per share (excluding the impact of amortization of acquired intangible assets)
|
|
$0.65
|
|
|
$0.64
|
|
|
$1.90
|
|
|
$1.82
|
|
||||
| (A) | Management excludes amortization of acquired intangible assets from its evaluation of ongoing operations and believes investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance. |
ResMed believes that presenting diluted earnings per share, excluding the impact of the amortization of acquired intangible assets is an additional measure of performance that investors can use to compare operating results between reporting periods.
Management uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Management believes this information provides investors better insight in evaluating the Companys performance from core operations and provides consistency in financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
- End -